SCHEMBL20949549

SCHEMBL20949549

O=C(Nc1ncc2ccc(-c3cnco3)cc2n1)c1ccc(OC(F)F)cc1

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 12/20 0.73
WNT1 P04628 9/20 0.47
GSK3B P49841 7/20 0.47
NPC1 O15118 4/20 0.43
PKM P14618 3/20 0.43
KDM4E B2RXH2 2/20 0.43
CLK2 P49760 3/20 0.43
CLK3 P49761 3/20 0.43
RAB9A P51151 3/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 2/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19516319 0.85 DYRK1A (1.00) DYRK1AWNT1GSK3BCLK2CLK3
SCHEMBL20950067 0.84 DYRK1A (0.50) DYRK1AWNT1GSK3BNPC1PKM
SCHEMBL20949593 0.81 DYRK1A (0.73) DYRK1AWNT1GSK3BNPC1PKM
SCHEMBL20951594 0.80 DYRK1A (0.73) DYRK1AWNT1GSK3BCLK2CLK3
SCHEMBL20950552 0.80 DYRK1A (0.55) DYRK1AWNT1GSK3BCLK2CLK3
SCHEMBL20947704 0.80 DYRK1A (0.75) DYRK1AWNT1GSK3BNPC1PKM
SCHEMBL20948468 0.79 DYRK1A (0.73) DYRK1AWNT1GSK3BNPC1PKM
SCHEMBL23048863 0.79 DYRK1A (0.89) DYRK1AWNT1GSK3BCLK2CLK3
SCHEMBL19546583 0.79 DYRK1A (0.89) DYRK1AWNT1GSK3BCLK2CLK3
SCHEMBL20948689 0.78 DYRK1A (0.78) DYRK1AWNT1GSK3BNPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US claimed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US claimed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 DYRK1A 1/4885WNT1 3/4885GSK3B 19/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 DYRK1A 1/4885WNT1 3/4885GSK3B 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.